4 курс / Акушерство и гинекология / Кабатин_Н_А_Течение_беременности_и_перинатальные_исходы_при_различных
.pdf131
22.Прилепская В.Н., Довлетханова Э.Р., Абакарова П.Р. Возможности терапии ВПЧ-ассоциированных заболеваний гениталий у женщин // Акушерство и гинекология. 2011. № 5. С. 123–128.
23.Прилепская В.Н., Костава М.Н., Назарова Н.М. и др. Эффективность применения Изопринозина при лечении вульводинии, обусловленной инфекционно-воспалительными процессами // Рус. мед. журн. ‒ 2009. ‒ Т. 17, №
16.‒ С. 1046–1048.
24.Прилепская В.Н., Роговская С.И. Возможности Изопринозина в лечении хронических цервицитов и вагинитов // Русский Медицинский Журнал. 2008. Т.
16.№ 1. С. 5–9.
25.Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки. Руководство для практ. врача. - М.: ГЭОТАР-Медиа, 2005.
26.Роговская С.И. Папилломавирусная инфекция. – 3-е изд., испр. и доп. –
M.:ГЭОТАР-Медиа,2010 – 240 с.
27.Роговская С.И. Практическая кольпоскопия – 3 – е изд., испр. и доп. -–
М.:ГЭОТАР-Медиа,2013. – 240 с.
28.Семена И.И. Папилломавирусная инфекция: Клинико-иммунологические особенности женщин и методы комбинированной терапии // Автореф. дис. ...
канд. мед. наук : 14.00.11, 14.00.10. - Спб.: Военно-медицинская академия им. С.М. Кирова, 2005. С. 26.
29.Солдатский Ю.Л., Онуфриева Е.К., Стрыгина Ю.В. и др. Рецидивирующий респираторный папилломатоз: современное решение проблемы. Вестник оториноларингологии, 2009, №4. С. 66-71.
30.Телетаева Г.М. Цитокины и противоопухолевый иммунитет // Практическая онкология. 2007. Т. 8. № 1. С. 211– 218.
31.Телешева Л.Ф. Иммунологические факторы секретов репродуктивного тракта женщин // Автореф. дис. ... докт. мед. наук: 14.00.01. Челябинск: Челябинский государственный медицинский институт, 2000. С. 41.
32.Тирская Ю. И. Рудакова Е. Б. Шакина И. А. и др. Роль цервицитов в акушерско-гинекологической патологии// Лечащий врач №10, 2009.
132
33.Урманчеева А.Ф. Рак шейки матки и беременность // Практическая онкология. 2002. Т. 3. № 3. С. 183–193.
34.Урманчеева А.Ф., Ульрих Е.А. Опухоли женских половых органов и беременность. Пособие для врачей. / под ред. Э.К. Айламазяна. – СПб.: ООО
“Издательство Н-Л,” 2011.
35.Фирченко С.В., Манухин И.Б., Минкина Г.Н., Фадеева Е.А. Расширенная биопсия шейки матки у беременных: преимущества и безопасность // Проблемы репродукции 2012. №1. С. 79-83.
36.Хофмейер Д.Ю., Нейлсон Д.П., Алфиревич З. и др.Кокрановское руководство: Беременность и роды/ Пер. с англ..-М.: Логосфера, 2010.-440 с.
37.Цинзерлинг, В.А. Перинатальные инфекции (вопросы патогенеза, морфологической диагностики и клинико-морфологических сопоставлений). Руководство для врачей Текст. / В.А. Цинзерлинг, В.Ф. Мельникова. СПб: Сотис.
— 2002. - 352с.
38.Черешнев В.А., Гусев Е.И. Иммунология воспаления: роль цитокинов // Медицинская иммунология. 2001. Т. 3. № 3. С. 361–368.
39.Чистяков М.А. Патоморфология папилломавирусной инфекции в системе “мать-плацента-плод” // Автореф. дис. ... канд. мед. наук : 14.00.15. Москва: ГУ НИИ морфологии человека РАМН, 2008. С. 27.
40.Шаргородская А.В. Клинико-эпидемиологические особенности папилломавирусной инфекции у молодых женщин: Автореф.дисс. …канд.мед.наук.:14.01.01. Mосква: ГБОУ ВПО МГМСУ имени А.И. Евдокимова МЗ РФ, 2013.С.24.
41.ACOG Practice Bulletin. Clinical Management Guidelines for ObstetricianGynecologists. Number 61, April 2005. Human papillomavirus. // Obstet. Gynecol. 2005. V. 105. № 4. P. 905–918.
42.Agorastos T., Miliaras D., Lambropoulos A. et al. Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III
133
intraepithelial neoplasia: biologic progression or independent lesions? // Eur. J. Obstet.
Gynecol. Reprod. Biol. 2005. V. 121. № 1. P. 99–103.
43.Alberico S., Pinzano R., Comar M. [Maternal-fetal transmission of human papillomavirus]. // Minerva Ginecol. 1996. V. 48. № 5. P. 199–204.
44.Al-Halal H., Kezouh A., Abenhaim H.A. Incidence and obstetrical outcomes of cervical intraepithelial neoplasia and cervical cancer in pregnancy: a population-based study on 8.8 million births. // Arch. Gynecol. Obstet. 2013. V. 287. № 2. P. 245–250.
45.Apgar B.S., Zoschnick L., Wright T.C. The 2001 Bethesda System terminology. // Am. Fam. Physician. 2003. V. 68. № 10. P. 1992–1998.
46.Armbruster-Moraes E., Ioshimoto L.M., Leão E. et al. Presence of human papillomavirus DNA in amniotic fluids of pregnant women with cervical lesions. // Gynecol. Oncol. 1994. V. 54. № 2. P. 152–158.
47.Baldauf J.J., Dreyfus M., Ritter J. et al. Colposcopy and directed biopsy reliability during pregnancy: a cohort study. // Eur. J. Obstet. Gynecol. Reprod. Biol. 1995. V. 62. № 1. P. 31–6.
48.Behbakht K., Friedman J., Heimler I. et al. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. // Infect. Dis. Obstet. Gynecol. 2002. V. 10. № 4. P. 181–186.
49.Benedet J.L., Selke P.A., Nickerson K.G. Colposcopic evaluation of abnormal Papanicolaou smears in pregnancy. // Am. J. Obstet. Gynecol. 1987. V. 157. № 4 Pt 1.
P. 932–937.
50.Bezold G., Politch J.A., Kiviat N.B. et al Prevalence of sexually transmissible pathogens in semen from asymptomatic male infertility patients with and without leukocytospermia. // Fertil. Steril. 2007. V. 87. № 5. P. 1087–97.
51.Bielanski A. Disinfection procedures for controlling microorganisms in the semen and embryos of humans and farm animals. // Theriogenology. 2007. V. 68. №1.P. 1–22.
52.Bosch F.X. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother. 2011. Oct №12(14). P. 2189-204.
53.Bosch F.X.,Broker T.R., Forman D. Comprehensive control of human papillomavirus infections and related diseases. ICO Monograph Comprehensive control
134
of human papillomavirus infections and related diseases in the central and Eastren
Europe and Central Asia region Vaccine V. 31, Supp.7,2013.
54.Boulet, G. A.V., Horvath, C. A.J., Berghmans, S., Bogers, J. Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker. -Cancer Epidemiol. Biomarkers Prev., 2008, V. P. 810-817.
55.Bouvard V., Baan R., Straif K. et al. A review of human carcinogens--Part B: biological agents // The lancet oncology. 2009. V. 10, № 4. P. 321–322.
56.Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. // Cancer Res. 1996. V. 56. № 20. P. 4620–4624.
57.Brandtzaeg P., Pabst R. Let’s go mucosal: communication on slippery ground. // Trends Immunol. 2004. V. 25. № 11. P. 570–577.
58.Brismar Wendel S., Kaldensjö T., Peterson P. et al. Slumbering mucosal immune response in the cervix of human papillomavirus DNA-positive and -negative women. // Int. J. Oncol. 2010. V. 37. № 6. P. 1565–1573.
59.Broder S. From the National Institutes of Health. // JAMA. 1992. V. 267. № 14.
P. 1892.
60. Broderick D., Matityahu D., Dudhbhai M. et al. Histologic and colposcopic correlates of ASCUS pap smears in pregnancy. // J. Low. Genit. Tract Dis. 2002. V. 6.
№ 2. P. 116–9.
61. Bruni |
L., Diaz |
M., Castellsagué |
X. |
et |
al. |
Cervical |
human |
papillomavirus prevalence in 5 continents: meta-analysis |
of 1 |
million women with |
|||||
normal cytological findings.J Infect Dis. 2010 Dec 15 № 202(12). P.1789-1799. |
|
||||||
62.Bunney M.H., Barr B.B., McLaren K. et al. Human papillomavirus type 5 and skin cancer in renal allograft recipients. // Lancet. 1987. V. 2. № 8551. P. 151–152.
63.Calinisan J.H., Chan S.R., King A. et al. Calinisan J.H. и др. Human papillomavirus and blastocyst apoptosis. // J. Assist. Reprod. Genet. 2002. V. 19. № 3.
P. 132–136.
64. Cason J., Mant C.A. High-risk mucosal human papillomavirus infections during infancy & childhood. // J. Clin. Virol. 2005. V. 32 Suppl 1. P. S52–58.
135
65.Cason J., Rice P., Best J.M. Transmission of cervical cancer-associated human papilloma viruses from mother to child. // Intervirology.1998.V. 41. № 4-5. P. 213–218.
66.Clerici M., Merola M., Ferrario E. et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. // J. Natl. Cancer Inst. 1997. V. 89. № 3. P. 245–50.
67.Cohen E., Levy A., Holcberg G. et al. Perinatal outcomes in condyloma acuminata pregnancies. // Arch. Gynecol. Obstet. 2011.V. 283. № 6. P. 1269–73.
68.Constandinou-Williams C., Stuart I.Collins, Roberts S. et al. Is Human Papillomavirus Viral Load a Clinically Useful. Predictive Marker? A Longitudinal Study // Cancer Epidemiol Biomarkers Prev. 2010.V.19. P. 832–837.
69.Creasman W.T. Cancer and pregnancy.// Ann. N.Y. Acad. Sci. 2001.V. 943. P. 281–286.
70.Derkay C.S., Wiatrak B. Recurrent respiratory papillomatosis: a review. // Laryngoscope. 2008. V. 118. № 7. P. 1236–1247.
71.Didelot-Rousseau M.N., Diafouka F., Yayo E. et al. HPV seminal shedding among men seeking fertility evaluation in Abidjan, Ivory Coast. // J.Clin.Virol. 2007. V. 39. № 2. P. 153–155.
72.DiPaolo J.A., Woodworth C.D., Popescu N.C. et al. HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes. // Virology. 1990. V. 177. № 2. P. 777–779.
73.DiSaia P.J., Creasman W.T. Clinical Gynecologic Oncology, Eighth Edition. Philadelphia, PA: Saunders Elsevier Inc., 2012 – 720 p.
74.Doerfler D., Bernhaus A., Kottmel A. et al. Human papilloma virus infection prior to coitarche. // Am. J. Obstet. Gynecol. 2009. V. 200. № 5. P. 487.e1–5.
75.Economos K., Perez Veridiano N., Delke I. et al. Abnormal cervical cytology in pregnancy: a 17-year experience. // Obstet. Gynecol. 1993. V. 81. № 6. P. 915–918.
76.Fader A.N., Alward E.K., Niederhauser A. et al. Cervical dysplasia in pregnancy: a multi-institutional evaluation //Am. J. Obstet. Gynecol.‒2010. – V. 203, № 2.– P. 113;
e1‒6.
136
77. Foresta C., Garolla A., Zuccarello D. et al. Human papillomavirus found in sperm head of young adult males affects the progressive motility. // Fertil. Steril. 2010. V. 93.
№ 3. P. 802–806.
78.Foresta C., Patassini C., Bertoldo A. et al. Mechanism of human papillomavirus binding to human spermatozoa and fertilizing ability of infected spermatozoa. // PLoS One. 2011. V. 6. № 3. P. e15036.
79.Foresta C., Pizzol D., Moretti A. et al. Clinical and prognostic significance of human papillomavirus DNA in the sperm or exfoliated cells of infertile patients and subjects with risk factors. // Fertil. Steril. 2010. V. 94. № 5.P. 1723–1727.
80.Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. // CMAJ. 2001. V. 164.
№ 7. P. 1017–1025.
81. Fredericks B.D., Balkin A., Daniel H.W. et al. Transmission of human papillomaviruses from mother to child. // Aust. N. Z. J. Obstet. Gynaecol. 1993.V. 33.
№ 1.P. 30–32.
82.Freitas A.C., Mariz F.C., Silva M.A.et al.Human papillomavirus vertical transmission: review of current data.//Clin. Infect. Dis. 2013. V. 56. № 10.P.1451–1456.
83.Garolla A., Pizzol D., Foresta C. The role of human papillomavirus on sperm function. // Curr. Opin. Obstet. Gynecol. 2011. V. 23. № 4. P. 232–237.
84.Gillet E., Meys J.F., Verstraelen H. et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. // BMC Infect. Dis. 2011.V. 11. № 1. P. 10.
85.Giovannelli L., Migliore M.C., Capra G. et al. Penile, urethral, and seminal sampling for diagnosis of human papillomavirus infection in men. // J. Clin. Microbiol. 2007. V. 45. № 1.P. 248–251.
86.Gomez L.M., Ma Y., Ho C. et al. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. // Hum. Reprod. 2008. V. 23. № 3.
P. 709–715.
137
87. Griffiths T.R., Mellon J.K. Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer. // BJU Int. 2000.V. 85. № 2.
P. 211–217.
88.Hajek E.F. Contribution to the etiology of laryngeal papilloma in children. // J. Laryngol. Otol. 1956. V. 70. № 3. P. 166–168.
89.Hamouda T., Freij M.A., Saleh M. Management of genital warts in pregnancy. Clin Exp Obstet Gynecol. 2012. №39(2). P.242-244.
90.Handley J., Dinsmore W. Treatment of anogenital warts. Review J European Acad Dermatol Venerol 1994.№ 3.P.251-265.
91.Heinrich P.C., Castell J. V, Andus T. Interleukin-6 and the acute phase response. // Biochem. J. 1990.V. 265. № 3. P. 621–636.
92.Hellberg D., Nilsson S. IVF and HPV. // Fertil. Steril. 2007. V. 87. № 6.P.1498
93.Henneberg A.A., Patton W.C., Jacobson J.D. et al. Human papilloma virus DNA exposure and embryo survival is stage-specific. // J. Assist. Reprod. Genet. 2006. V. 23.
№ 6. P. 255–259.
94.Hermonat P.L., Han L., Wendel P.J. et al. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. // Virus Genes. 1997.V.14. № 1.P. 13–17.
95.Hermonat P.L., Kechelava S., Lowery C.L. et al.. Trophoblasts are the preferential target for human papilloma virus infection in spontaneously aborted products of conception. // Hum. Pathol. 1998.V. 29. № 2. P. 170–174.
96.Hesselink A.T., Berkhof J., Heideman D.A. et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer // Int J Cancer. 2009.№124.P.381.
97.Hubbert N.L., Sedman S.A., Schiller J.T. Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. // J. Virol. 1992.V.66.
№ 10. P. 6237–6241.
138
98.Hunter M.I., Monk B.J., Tewari K.S. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. // Am. J. Obstet. Gynecol. 2008. V.199. № 1. P. 3–9.
99.Kaye J.N., Cason J., Pakarian F.B. et al. Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. // J. Med. Virol. 1994. V. 44. № 4.P. 415–421.
100.Khan M., Castle P. E., Lorincz A. T. et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice. J Natl Cancer Inst. 2005.№97.P.1072 – 1079.
101.Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.//Altern. Med. Rev. -2003 Aug. - Vol. 8(3). - Р.223-246.
102.Kjær S., Frederiksen K., Munk C. et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. // J. Natl. Cancer Inst. 2010. V. 102. № 19. P. 1478–1488.
103.Kjaer S.K., Chackerian B., van den Brule A.J. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). // Cancer Epidemiol. Biomarkers Prev. 2001.V.10. № 2. С.101–106.
104.Koch A., Hansen S.V., Nielsen N.M. et al. HPV detection in children prior to sexual debut. // Int. J. Cancer. 1997.V.73. № 5.P.621–624.
105.Kohan S., Beckman E.M., Bigelow B. et al. The role of colposcopy in the management of cervical intraepithelial neoplasia during pregnancy and postpartum. // J. Reprod. Med. 1980. V. 25. № 5. P. 279–284.
106.Kŭlvachev Z., Draganov P., Minkov L. HPV and spontaneous abortion: results from a virological study Akush Ginekol (Sofiia). 2007.№46(6).P.8-12
107.Lacour D.E., Trimble C. Human papillomavirus in infants: transmission, prevalence, and persistence. // J. Pediatr. Adolesc. Gynecol. 2012. V. 25. № 2. P. 93–97.
108.Lai C.H., Hsueh S., Lin C.Y. et al. Human papillomavirus in benign and
malignant ovarian and endometrial tissues. // Int. J. Gynecol. Pathol. 1992.V.11. № 3.
P. 210–215.
139
109. Lai Y.M., Yang F.P., Pao C.C. Human papillomavirus deoxyribonucleic acid and ribonucleic acid in seminal plasma and sperm cells. // Fertil. Steril. 1996.V. 65. № 5.
P.1026–1030.
110. Laudadio J. Human papillomavirus detection: testing methodologies and their clinical utility in cervical cancer screening. // Adv. Anat. Pathol. 2013.V.20. № 3.
P.158–167.
111.Lindsey C.L., Almeida M.E., Vicari C.F. et al. Bovine papillomavirus DNA in milk, blood, urine, semen, and spermatozoa of bovine papillomavirus-infected animals. // Genet. Mol. Res. 2009.V. 8. № 1. P. 310–318.
112.Louie K.S., Castellsague X., de Sanjose S. et al. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. Cancer Epidemiol Biomarkers Prev. 2011. №20(7). P.1379-1390.
113.Luks S., Simon R.A., Lawrence W.D. Arias-Stella reaction of the cervix: The enduring diagnostic challenge. // Am. J. Case Rep. 2012. V. 13. P. 271–275.
114.Lundqvist M., Westin C., Lundkvist O. et al. Cytologic screening and human papilloma virus test in women undergoing artificial fertilization. // Acta Obstet. Gynecol. Scand.2002.V. 81. № 10. P. 949–53.
115.Maluf M., Perin P. HPV e gestação // Brazil Press, 2005. P. 193–225.
116.Marcoux D., Nadeau K., McCuaig C. et al. Marcoux D. и др. Pediatric anogenital warts: a 7-year review of children referred to a tertiary-care hospital in Montreal, Canada. // Pediatr. Dermatol. 2006. V. 23. № 3. P. 199–207.
117.Marinho-Dias J., Sousa H. Cytomegalovirus infection and cervical cancer: from past doubts to present questions. // Acta Med. Port. 2013. V. 26. № 2. P. 154–60.
118.Massad L.S., Einstein M.H., Huh W.K. et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. // J. Low. Genit. Tract Dis. 2013. V. 17. № 5 Suppl 1. P. S1–S27.
119.Matovina M., Husnjak K., Milutin N. et al. Possible role of bacterial and viral infections in miscarriages. // Fertil. Steril. 2004. V. 81. № 3. P. 662–669.
120.Matsumoto K., Oki A, Furuta R et al. Tobacco smoking and regression of lowgrade cervical abnormalities.// Cancer Sci. 2010.№101(9).P.2065-2073.
140
121.McBride A.A., Romanczuk H., Howley P.M. The papillomavirus E2 regulatory proteins. // J. Biol. Chem. 1991. V. 266. № 28. P. 18411–18414.
122.McIntyre-Seltman K., Lesnock J.L. Cervical cancer screening in pregnancy. // Obstet. Gynecol. Clin. North Am. 2008. V. 35. № 4. P. 645–658.
123.Medeiros L.R., Ethur A.B., Hilgert J.B. et al. Vertical transmission of the human papillomavirus: a systematic quantitative review. // Cad. Saude Publica. 2005. V. 21.
№ 4. P. 1006–1015.
124.Monroy O.L., Aguilar C., Lizano M. et al. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy. // J. Clin. Virol. 2010. V. 47. № 1. P. 43–48.
125.Moore K., de Waal Malefyt R., Coffman R.L. Interleukine-10 and interleukine-10 receptor // Ann. Rev. Immunol. 2001. V. 19. P. 683-765.
126.Morimura Y., Fujimori K., Soeda S. et al. Cervical cytology during pregnancy-- comparison with non-pregnant women and management of pregnant women with abnormal cytology. // Fukushima J. Med. Sci. 2002. V. 48. № 1. P. 27–37.
127.Mota F., Calder V., Rutault K. et al. Characterization of soluble factors from cultures of premalignant cervical epithelium. // Eur. J. Gynaecol. Oncol. 1999. V. 20.
№ 4. P. 262–267.
128.Mota F., Rayment N., Chong S. et al. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. // Clin. Exp. Immunol. 1999. V. 116. № 1. P. 33–40.
129.Motevaseli E., Shirzad M., Akrami S.M. et al. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. // J. Med. Microbiol. 2013. Т. 62. № Pt 7. P. 1065–1072.
130.Myhre A.K., Dalen A., Berntzen K. et al. Anogenital human papillomavirus in non-abused preschool children. // Acta Paediatr. 2003. V. 92. № 12. P. 1445–1452.
131. Natphopsuk S., Settheetham-Ishida W., Sinawat S et al. Risk factors
for cervical cancer in northeastern Thailand: detailed analyses of sexual and smoking behavior.// Asian Pac J Cancer Prev. 2012.№13(11).P.5489-5495.